Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2.

Interleukin 2 (IL-2) immunotherapy has met with limited success in the treatment of renal cell carcinoma (RCC) and malignant melanoma (MM). However, non-responders still account for up to 80% of those patients receiving IL-2. A high concentration of soluble IL-2 receptor (sIL-2R) is commonly found i...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Gooding, R., Riches, P., Dadian, G., Moore, J., Gore, M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 1995
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2033994/
https://ncbi.nlm.nih.gov/pubmed/7640231
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak